Benzinga | Jul 20, 2020 08:14AM EDT

Credit Suisse Maintains Neutral on Neurocrine Biosciences, Raises Price Target to $135

Credit Suisse maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and raises the price target from $101 to $135.